These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 27892684)

  • 21. Angiotensin receptor neprilysin inhibition in heart failure: mechanistic action and clinical impact.
    Buggey J; Mentz RJ; DeVore AD; Velazquez EJ
    J Card Fail; 2015 Sep; 21(9):741-50. PubMed ID: 26209000
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term neprilysin inhibition - implications for ARNIs.
    Campbell DJ
    Nat Rev Cardiol; 2017 Mar; 14(3):171-186. PubMed ID: 27974807
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First-in-Class Composite Angiotensin Receptor-Neprilysin Inhibitors (ARNI) in Practice.
    Barghash MH; Desai AS
    Clin Pharmacol Ther; 2017 Aug; 102(2):265-268. PubMed ID: 28512738
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neprilysin Inhibitors in Cardiovascular Disease.
    Kang G; Banerjee D
    Curr Cardiol Rep; 2017 Feb; 19(2):16. PubMed ID: 28185171
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sacubitril/valsartan: An important piece in the therapeutic puzzle of heart failure.
    Marques da Silva P; Aguiar C
    Rev Port Cardiol; 2017 Sep; 36(9):655-668. PubMed ID: 28844335
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pre-treatment with LCZ696, an orally active angiotensin receptor neprilysin inhibitor, prevents ischemic brain damage.
    Bai HY; Mogi M; Nakaoka H; Kan-No H; Tsukuda K; Chisaka T; Wang XL; Kukida M; Shan BS; Yamauchi T; Higaki A; Iwanami J; Horiuchi M
    Eur J Pharmacol; 2015 Sep; 762():293-8. PubMed ID: 26057694
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of Neprilysin Inhibitors in Heart Failure.
    Salazar Adum JP; Arora R
    Am J Ther; 2017; 24(6):e737-e743. PubMed ID: 26580582
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan.
    Jhund PS; McMurray JJ
    Heart; 2016 Sep; 102(17):1342-7. PubMed ID: 27207980
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neprilysin Inhibition as a PARADIGM Shift in Heart Failure Therapy.
    Hsiao R; Greenberg B
    Curr Heart Fail Rep; 2016 Aug; 13(4):172-80. PubMed ID: 27271564
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dual Angiotensin Receptor and Neprilysin Inhibition with Sacubitril/Valsartan in Chronic Systolic Heart Failure: Understanding the New PARADIGM.
    Lillyblad MP
    Ann Pharmacother; 2015 Nov; 49(11):1237-51. PubMed ID: 26175499
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of Angiotensin Receptor-Neprilysin Inhibition in Heart Failure.
    Prenner SB; Shah SJ; Yancy CW
    Curr Atheroscler Rep; 2016 Aug; 18(8):48. PubMed ID: 27324636
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances.
    McMurray JJ
    Eur J Heart Fail; 2015 Mar; 17(3):242-7. PubMed ID: 25756942
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Angiotensin Receptor-Neprilysin Inhibition.
    Havakuk O; Elkayam U
    J Cardiovasc Pharmacol Ther; 2017 Jul; 22(4):356-364. PubMed ID: 28587583
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696.
    Jhund PS; Claggett BL; Voors AA; Zile MR; Packer M; Pieske BM; Kraigher-Krainer E; Shah AM; Prescott MF; Shi V; Lefkowitz M; McMurray JJ; Solomon SD;
    Circ Heart Fail; 2014 Nov; 7(6):953-9. PubMed ID: 25277997
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists.
    Ambrosy AP; Braunwald E; Morrow DA; DeVore AD; McCague K; Meng X; Duffy CI; Rocha R; Velazquez EJ;
    J Am Coll Cardiol; 2020 Sep; 76(9):1034-1048. PubMed ID: 32854838
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).
    Gu J; Noe A; Chandra P; Al-Fayoumi S; Ligueros-Saylan M; Sarangapani R; Maahs S; Ksander G; Rigel DF; Jeng AY; Lin TH; Zheng W; Dole WP
    J Clin Pharmacol; 2010 Apr; 50(4):401-14. PubMed ID: 19934029
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The angiotensin II type 1 receptor-neprilysin inhibitor LCZ696 blocked aldosterone synthesis in a human adrenocortical cell line.
    Miura SI; Suematsu Y; Matsuo Y; Tomita S; Nakayama A; Goto M; Arimura T; Kuwano T; Yahiro E; Saku K
    Hypertens Res; 2016 Nov; 39(11):758-763. PubMed ID: 27334058
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The potential role of valsartan + AHU377 ( LCZ696 ) in the treatment of heart failure.
    Voors AA; Dorhout B; van der Meer P
    Expert Opin Investig Drugs; 2013 Aug; 22(8):1041-7. PubMed ID: 23663006
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sacubitril/valsartan (LCZ696) significantly reduces aldosterone and increases cGMP circulating levels in a canine model of RAAS activation.
    Mochel JP; Teng CH; Peyrou M; Giraudel J; Danhof M; Rigel DF
    Eur J Pharm Sci; 2019 Feb; 128():103-111. PubMed ID: 30508581
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Focused Treatment of Heart Failure with Reduced Ejection Fraction Using Sacubitril/Valsartan.
    Liu RC
    Am J Cardiovasc Drugs; 2018 Dec; 18(6):473-482. PubMed ID: 29850980
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.